Just my opinion but I don't think current share price has much to do with exercising warrants that are eligible to be exercised in this window. Most of the holders of these warrants have a long view and exercising is non dilutive support for their investment. I think a much more important consideration wrt exercising is what management is telling these holders as to why they should exercise now. In any event I'm sure there was very serious discussions with these holders prior to announcing the exercise incentive program. 

As far as pricing Resverlogix goes I think RVX will be able to garner a larger premium than many other biotechs because although Apabetalone has huge potential on its own, the company as a whole may be viewed by a purchasing pharma as a strong platform for future epigentic drug development. It is not just RVX that feels they are a leader in epigenetics and there is a growing school of thought viewing epigenetics as an important area for future medical advancement.